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Background: While acute kidney injury (AKI) alone is associated with increased mortality, 
the incidence of hospital admission with AKI among stable and exacerbating COPD patients 
and the effect of concurrent AKI at COPD exacerbation on mortality is not known.
Methods: A total of 189,561 individuals with COPD were identified from the Clinical 
Practice Research Datalink. Using Poisson and logistic regressions, we explored which factors 
predicted admission for AKI (identified in Hospital Episode Statistics) in this COPD cohort 
and concomitant AKI at a hospitalization for COPD exacerbation. Using survival analysis, we 
investigated the effect of concurrent AKI at exacerbation on mortality (n=36,107) and identi-
fied confounding factors.
Results: The incidence of AKI in the total COPD cohort was 128/100,000 person-years. The 
prevalence of concomitant AKI at exacerbation was 1.9%, and the mortality rate in patients with 
AKI at exacerbation was 521/1,000 person-years. Male sex, older age, and lower glomerular filtra-
tion rate predicted higher risk of AKI or death. There was a 1.80 fold (95% confidence interval: 
1.61, 2.03) increase in adjusted mortality within the first 6 months post COPD exacerbation in 
patients suffering from AKI and COPD exacerbation compared to those who were AKI free.
Conclusion: In comparison to previous studies on general populations and hospitalizations, 
the incidence and prevalence of AKI is relatively high in COPD patients. Coexisting AKI at 
exacerbation is prognostic of poor outcome.
Keywords: acute renal failure, mortality, emphysema, chronic bronchitis, prognosis
Introduction
COPD affects 9%–10% of people over 40 years of age.1,2 It is the fifth biggest killer in 
the UK, and direct UK health care costs secondary to COPD equate to £805 million.3 
High levels of comorbidities, including ischemic heart disease, heart failure (HF), 
diabetes mellitus (DM), and chronic kidney disease (CKD), contribute to morbidity 
costs and mortality rates in COPD.4–6 CKD is often seen even in mild COPD cases, and 
can be largely attributed to both older age and smoking.5,7,8 Although CKD is debilitat-
ing on its own, its presence in COPD patients is particularly important as many COPD 
medications are metabolized by the kidney.7 Acute kidney injury (AKI) is defined as 
a rapid decline in renal function from baseline occurring over several hours or days,9 
more specifically, an absolute rise in the creatinine level by at least 26.4 µmol/L in 
48 hours.10 People with underlying reduced estimated glomerular filtration rate (eGFR) 
and even those with mild proteinuria are at increased risk of AKI.11–13 Although by 
definition AKI is reversible, the notion of reversibility is too simplistic; worsening 
renal function is commonly observed following AKI.9,14
Given that CKD is more prevalent in people with COPD than without and given 
that CKD is a risk factor for AKI, it is possible that the rate of AKI is higher among 
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COPD patients than in people without COPD. Additionally, 
at the time of a COPD exacerbation, when gaseous exchange 
within the lungs may become less effective and carbon 
dioxide retention can occur, reduced renal blood flow and 
hence GFR can result.15–18 Therefore, it is likely that there 
is a higher prevalence of AKI in patients hospitalized with 
COPD exacerbations than general hospitalizations. While 
AKI has been associated with larger mortality rates in people 
with community-acquired pneumonia, there are no published 
studies investigating mortality in COPD patients in the pres-
ence of AKI.19
Our overarching hypothesis was that people with COPD 
are at increased risk of AKI. Using linked Clinical Practice 
Research Datalink (CPRD) and Hospital Episode Statistics 
(HES) data, we addressed several specific questions: 1) we 
quantified the incidence and potential risk factors for hospital 
admission with AKI in a cohort of COPD patients; 2) we 
determined the prevalence of and possible risk factors for 
AKI among people hospitalized with a COPD exacerbation; 
and 3) we investigated mortality rates following hospitaliza-
tion for COPD exacerbation stratified by AKI at admission, 
adjusted for confounding factors.
Methods
Data sources
CPRD is the world’s largest validated computerized database 
of anonymized longitudinal medical records for primary care.20 
Data comprise approximately 14 million patients with approxi-
mately 5.4 million of them currently alive and registered at 660 
primary care practices spread throughout the UK.20 Records are 
derived from the Vision software system and contain complete 
prescribing and coded diagnostic and clinical information as 
well as information on tests requested, laboratory results, and 
referrals made at or following on from each consultation.20 
The population of patients within CPRD are representative of 
the UK population with respect to age, sex, and geographical 
distribution. Over 60% of the English practices have consented 
to linkage with HES. HES data contain information on all NHS 
inpatient admissions in England, with the main and subsidiary 
reasons for admission coded using the tenth revision of the 
International Statistical Classification of Diseases and Related 
Health Problems (ICD-10).21
study population of patients with COPD
The main study population consisted of individuals over 
35 years old, with at least 1 year of historical data, evidence 
of having ever smoked, and a diagnosis of COPD. COPD 
was identified in CPRD using validated Read Codes.22 Study 
entry occurred on the latest of the following dates: January 1, 
2004; 1 year after registration with the practice; or 1 year 
after the practice quality standards were met for inclusion 
in CPRD. Study exit was the earliest of the following dates: 
patient transfer-out date, patient death, or December 31, 
2012. CPRD records were linked with HES data to identify 
patients who were hospitalized and the reason for their hos-
pitalization. Patients were excluded if they had no follow-up 
data or a known history of renal dialysis or transplant (renal 
replacement therapy) and Read Codes from CPRD of CKD 
stage 5 or end-stage renal failure (Figure 1).
Identification of first COPD exacerbation 
during follow-up
To study the prevalence of and risk factors for concurrent 
AKI at the first COPD exacerbation and subsequent mortal-
ity, patients within the main study population experiencing at 
least one COPD exacerbation with available follow-up data 
were identified (Figure 1). Patients entered this subpopulation 
at the first record of COPD exacerbation after study entry 
&23'SDWLHQWVLQ&35'-DQXDU\±'HFHPEHU!\HDUVROG\HDUVKLVWRU\RIVPRNLQJQ 
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Figure 1 Flowchart of participant inclusion.
Abbreviations: CPrD, Clinical Practice research Datalink; CKD, chronic 
kidney disease; aKI, acute kidney injury; COPD, chronic obstructive pulmonary 
disease.
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and left at study exit as defined above. COPD exacerbations 
were identified from HES records as any hospitalization 
where the primary reason for admission was described 
using ICD-10 code for infective exacerbation of COPD with 
ICD-10 code J44 Chronic Obstructive Pulmonary Disease 
with (Acute) Exacerbation. Repeat COPD exacerbations 
were not included.
Definition of outcomes
Similarly, AKI was identified from HES records as any 
hospitalization where the primary reason for admission was 
described with ICD-10 code N17 Acute Kidney Failure. For 
the description of COPD exacerbations, the primary outcome 
was the presence of coexisting AKI in any diagnostic position 
in HES records at the time of hospital admission for a COPD 
exacerbation. For the description of mortality following 
COPD exacerbation, the outcome was all-cause mortality, 
identified based on CPRD records.
explanatory variables
Demographic data included the patient’s age, sex, and region in 
England. COPD severity was categorized according to Global 
initiative for chronic Obstructive Lung Disease (GOLD) 
stage and recorded.23 Body mass index (BMI) was catego-
rized as per the World Health Organization classification24: 
underweight (,18.5 kg/m2), normal (18.5–24 kg/m2), over-
weight (25–29 kg/m2), obese (30–34 kg/m2), moderately 
obese (35–39 kg/m2), severely obese (40–44 kg/m2), and 
morbidly obese ($45 kg/m2). Comorbidities were identified 
by the presence of a diagnostic Read Code in CPRD: hyper-
tension (HTN), DM, angina, previous myocardial infarction, 
atrial fibrillation, HF, history of coronary artery bypass graft 
(CABG), and pulmonary HTN. Data regarding COPD and 
diabetic or cardiovascular medications (antiplatelets, beta 
blockers, diuretics, angiotensin-converting enzyme inhibitors/
angiotensin receptor blocker, antiarrhythmic, anticoagulant, 
lipid lowering, nitrate, calcium channel blocker) were identi-
fied from primary care prescriptions generated in CPRD.
For the total cohort of patients with COPD, the availability 
of serum creatinine test results was low, and we used diagnos-
tic Read Codes to identify CKD. The diagnosis and coding 
of CKD in primary care evolved during the study period. 
CKD staging based on eGFR was introduced in 2006, but 
many GPs continued to use the actual renal diagnosis rather 
than the GFR staging (CKD), thus capturing the renal disease 
etiology of the patient rather than renal function. We classified 
patients as having: 1) a diagnosis of CKD stage 3–4 (CKD); 
2) a diagnosis of likely renal impairment (renal disease), 
including microalbuminuria, proteinuria, or previous AKI 
admissions; or 3) no diagnosis of renal disease (no CKD). 
For patients with at least one COPD exacerbation, serum 
creatinine test results were complete, and we estimated eGFR 
from serum creatinine tests in primary care closest to the date 
of exacerbation (no less than 2 weeks prior to episode) using 
the CKD-Epidemiology Collaboration equation.25,26
Although smoking is a known risk factor for mortality, 
CKD, and COPD, we were only able to categorize patients 
as ex-smokers or current smokers and could not quantify any 
further than that. As patients had to be ex- or current smokers 
to be included in the COPD cohort to begin with, we did not 
use smoking status as an explanatory variable.
statistical methods
Poisson regression models were used to estimate associa-
tions between potential explanatory variables and crude AKI 
incidence. Given the large size of the dataset, it is inevitable 
that there will be a strong evidence of differences across 
explanatory categories during univariable analysis, and to 
avoid over adjusting, only age and sex were added to the 
multivariable model to calculate the observed age and sex-
adjusted AKI incidence. The association between patient 
characteristics and prevalence of AKI at COPD exacerbation 
was analyzed using logistic regression to calculate crude 
and adjusted odds ratios. The relationship between AKI and 
death following COPD exacerbation was investigated using 
Poisson regression models to calculate rate ratios of death and 
AKI, crude and adjusted for potential confounders. A forward 
causal modeling approach was used, with eGFR, age, and sex 
considered as a priori confounders. Other significant factors 
such as DM, HF, HTN, myocardial infarction, and CABG 
all are associated with a risk of CKD. Hence, including them 
in the multivariable analysis will contribute an element of 
collinearity. Thus, a simple approach was taken in the mul-
tivariable analysis: including only a priori confounders.
Evaluation of missingness was carried out by compar-
ing the observed outcome of interest (AKI) in the group 
where data on BMI and COPD severity are available to 
those where they are not. For all models, a complete case 
analysis approach was used and patients with missing BMI 
or COPD severity data were excluded. All statistical analyses 
were performed using Stata 12.1 statistical analysis software 
(StataCorp LP, College Station, TX, USA).
ethics
Ethics approval was obtained from the Independent Scientific 
Advisory Committee to CPRD (reference 13_086) and the 
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committee.
Results
We included 189,561 participants with COPD, of whom 
36,107 (19.0%) had records of at least one COPD exacer-
bation with follow-up encounters (Figure 1). The mean age 
of the overall cohort was 64.0 years (SD: 13.6). Most of 
the cohort (78.9%) did not have known CKD identified by 
CPRD Read Codes (Table 1). The cohort was followed up 
for a median time of 2.3 years.
With regard to missing data, only approximately 4% 
BMI data were missing in both the stable and exacerbation 
of COPD dataset, resulting in an almost negligible effect on 
the full dataset; therefore, complete case analysis was used 
to construct any model. A more substantive proportion of 
41% of stable COPD patients were missing COPD severity. 
There was no evidence of a difference in AKI between 
individuals with and without COPD severity data. Although 
missing at random cannot be assumed, we decided to carry 
out complete case analysis for this cohort. A total of 17.8% 
of the exacerbation cohort was missing COPD severity data. 
There is a clear difference in AKI events between samples 
with and without this data in the exacerbation cohort; hence, 
the data are not missing at random. The overall missingness 
remains below 20%, and for the sake of simplicity, complete 
case analysis was executed.
aim 1: Incidence of aKI among the 
cohort of patients with COPD
Among the total COPD cohort, 1,610 patients experienced 
hospitalization for AKI, yielding an incidence rate of 
128/10,000 person-years (128/105 py, 95% CI: 121, 134). 
The incidence of AKI was higher among men than women 
and rose with increasing age (Table 1).
The observed relationship of COPD severity with AKI 
incidence demonstrated increasing AKI rates with wors-
ening COPD severity, with a drop in patients with most 
severe COPD (GOLD stage IV). AKI incidence rates were 
dramatically higher in patients with CKD (370/105 py) or 
renal disease (1,081/105 py) compared to those with no CKD 
(41/105 py).
Comorbidities had an effect on the incidence of AKI in 
the COPD cohort. The rate of AKI among patients suffer-
ing from HF was 6.36 times (95% CI: 5.76, 7.03) higher 
than that among patients not diagnosed with HF. Patients 
with diagnosed CKD or renal disease had a 8.95-fold (95% 
CI: 7.96, 10.06) or a 26.16-fold (95% CI: 22.48, 30.43) 
increase in the rate of AKI compared to those with no CKD, 
respectively. The increased AKI incidence associated with 
other comorbidities ranged from a 2.26-fold increase (95% 
CI: 2.02, 2.53) for angina to a 3.31-fold increase (95% CI: 
2.46, 4.46) for pulmonary HTN. All studied medications 
were associated with increased rates of AKI, particularly 
diuretics and inotropes producing crude risk ratios (RRs) 
of 7.67 (95% CI: 6.5, 8.98) and 4.27 (95% CI: 3.82, 4.79), 
respectively, with negligible change when adjusted for 
age and sex.
aim 2: Prevalence of aKI during 
hospitalization for exacerbation of COPD
AKI was present in 704 of 36,107 COPD exacerbations 
(1.9%). The odds of AKI in COPD exacerbations were 26% 
lower in women compared to men (OR =0.74, 95% CI: 0.63, 
0.86). The prevalence of concurrent AKI increased with age, 
from 0.4% among patients aged ,50 years to 3.5% among 
patients $90 years of age (crude OR =9.21, 95% CI: 3.64, 
23.33). Prevalence of AKI was strongly associated with 
reduced eGFR before and after adjusting for age and sex. 
AKI was also more prevalent among patients with HTN, 
DM, atrial fibrillation, and HF in crude analyses. Evidence 
of association of AKI with HTN and HF remained after 
adjusting for age, sex, and eGFR (Table 2).
aim 3: aKI and mortality following 
COPD exacerbation
Among the 36,107 patients hospitalized for a COPD exacer-
bation, 14,447 died during follow-up (40%). The mean age 
of those who died was 73.9 years (SD: 9.4). Mortality rates 
rose with increasing age category from 35/1,000 person-years 
(35/103 py) in the youngest to 397/103 py in the oldest group. 
Mortality was lower among women than men (RR =0.87, 
95% CI: 0.84, 0.90), both before and after adjusting for age 
and eGFR (Table 3).
Reduced eGFR was strongly associated with increased 
mortality, but the relationship appeared J-shaped, with 
higher mortality among patients with eGFR $90 than 
patients with eGFR 60–89 or 30–59 mL/min/1.73 m2 after 
adjusting for age and sex. BMI was also strongly associated 
with mortality, with the highest mortality found in under-
weight individuals in comparison to those with normal BMI 
(adjusted RR =1.41, 95% CI: 1.30, 1.52). There was a graded 
association between worsening severity of COPD and higher 
mortality. Diagnosed HTN or DM, a history of CABG, 
and prescriptions of COPD medication, beta blockers, 
vasodilators, nitrates, antiarrhythmics, and lipid-lowering 
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Table 1 Baseline characteristics of all patients with COPD (n=189,561) and incidence aKI (n=1,610)
Baseline patient 
characteristics
Total at 
baseline, n (%)
With AKI, n 
(rate/100,000 py)
Crude rate ratio 
of AKI (95% CI)
P-valuea Adjustedb rate ratio 
of AKI (95% CI)
P-valuea
sex
Male 90,466 (47.7) 926 (157) 1 (reference) ,0.001 1 (reference) ,0.001
Female 99,095 (52.3) 684 (95) 0.65 (0.59, 0.72) 0.66 (0.60, 0.73)
age (years)
,50 30,761 (16.2) 30 (14) 1 (reference) ,0.001 1 (reference) ,0.001
50–59 37,538 (19.8) 125 (38) 3.27 (2.20, 4.88) 3.19 (2.14, 4.75)
60–69 49,422 (26.1) 354 (102) 7.43 (5.12, 10.79) 7.14 (4.92, 10.37)
70–79 46,174 (24.4) 640 (219) 15.84 (10.98, 22.84) 15.30 (10.61, 22.06)
80–89 22,822 (12.0) 423 (368) 26.68 (18.43, 38.64) 26.42 (18.25, 38.27)
$90 2,844 (1.5) 38 (380) 27.52 (17.04, 44.41) 28.66 (17.76, 46.27)
region
london 20,819 (11.0) 199 (146) 1 (reference) ,0.001 1 (reference) ,0.001
Midlands 31,903 (16.8) 236 (114) 0.78 (0.64, 0.94) 0.77 (0.64, 0.93)
north england 51,093 (27.0) 487 (142) 0.97 (0.83, 1.15) 1.02 (0.86, 1.20)
south england 85,746 (45.2) 688 (120) 0.82 (0.70, 0.96) 0.80 (0.68, 0.93)
Comorbidities
Body mass index
Underweight 5,313 (2.8) 33 (106) 1.29 (0.91, 1.85) ,0.001 1.42 (0.99, 2.02) ,0.001
normal 76,011 (40.1) 418 (82) 1 (reference) 1 (reference)
Overweight 64,683 (34.1) 592 (134) 1.63 (1.44, 1.85) 1.43 (1.26, 1.63)
Moderately obese 24,846 (13.1) 299 (178) 2.16 (1.87, 2.51) 2.15 (1.85, 2.49)
severely obese 7,324 (3.9) 123 (251) 3.06 (2.50, 3.74) 3.80 (3.10, 4.65)
Morbidly obese 3,149 (1.7) 55 (264) 3.22 (2.43, 4.26) 5.17 (3.89, 6.86)
Missing 8,138 (4.3) 90 (238) – –
COPD severity (gOlD stage)
I 24,507 (12.9) 145 (81) 1 (reference) ,0.001 1 (reference) ,0.001
II 53,697 (28.3) 514 (138) 1.70 (1.41, 2.04) 1.42 (1.18, 1.71)
III 26,626 (14.1) 295 (172) 2.12 (1.74, 2.59) 1.55 (1.27, 1.90)
IV 7,007 (3.7) 51 (126) 1.56 (1.13, 2.14) 1.15 (0.84, 1.59)
Missing 77,724 (41.0) 605 (123)
hypertension 89,824 (47.4) 1,161 (191) 2.75 (2.47, 3.07) ,0.001 1.89 (1.69, 2.11) ,0.001
Diabetes mellitus 33,042 (17.4) 613 (272) 2.82 (2.55, 3.12) ,0.001 2.50 (2.26, 2.77) ,0.001
angina 25,291 (13.3) 398 (226) 2.26 (2.02, 2.53) ,0.001 1.48 (1.32, 1.66) ,0.001
Myocardial infarction 16,872 (8.9) 333 (288) 2.90 (2.57, 3.27) ,0.001 1.92 (1.70, 2.17) ,0.001
Atrial fibrillation 22,065 (11.6) 457 (330) 3.20 (2.87, 3.56) ,0.001 1.84 (1.64, 2.05) ,0.001
heart failure 21,778 (11.5) 652 (537) 6.36 (5.76, 7.03) ,0.001 3.82 (3.44, 4.24) ,0.001
Coronary artery bypass graft 5,305 (2.8) 130 (366) 3.03 (2.53, 3.64) ,0.001 2.13 (1.78, 2.56) ,0.001
Pulmonary hypertension 1,963 (1.0) 45 (416) 3.31 (2.46, 4.46) ,0.001 2.37 (1.76, 3.18) ,0.001
Kidney disease
CKD stage 3–4 35,090 (18.5) 918 (370) 8.95 (7.96, 10.06) ,0.001 5.90 (5.22, 6.67) ,0.001
renal diseasec 4,835 (2.6) 286 (1,081) 26.16 (22.48, 30.43) 19.67 (16.87, 22.92)
Medications
COPD medications 160,121 (84.5) 1,428 (135) 1.51 (1.29, 1.76) ,0.001 1.38 (1.18, 1.61) 0.001
antiplatelets 105,831 (55.8) 1,184 (215) 3.59 (3.21, 4.01) ,0.001 2.08 (1.86, 2.34) ,0.001
antidiabetes medications 23,591 (12.5) 495 (311) 3.06 (2.75, 3.40) ,0.001 2.85 (2.56, 3.17) ,0.001
Beta blockers 61,155 (32.3) 787 (184) 1.85 (1.68, 2.04) ,0.001 1.53 (1.39, 1.69) ,0.001
Diuretics 101,116 (53.3) 1,437 (220) 7.67 (6.55, 8.98) ,0.001 4.72 (4.00, 5.56) ,0.001
aCei/arB 79,359 (41.9) 1,155 (217) 3.46 (3.10, 3.86) ,0.001 2.37 (2.12, 2.65) ,0.001
Vasodilators 11,292 (6.0) 43 (53) 0.40 (0.29, 0.54) ,0.001 0.53 (0.39, 0.71) ,0.001
alpha blockers 7,338 (3.9) 167 (342) 2.87 (2.44, 3.36) ,0.001 2.00 (1.71, 2.35) ,0.001
Inotropes 15,477 (8.2) 398 (444) 4.27 (3.82, 4.79) ,0.001 2.40 (2.14, 2.70) ,0.001
nitrates 26,114 (13.8) 395 (236) 2.12 (1.89, 2.38) ,0.001 1.59 (1.41, 1.78) 0.002
Calcium channel blockers 58,611 (30.9) 745 (184) 1.81 (1.64, 2.00) ,0.001 1.36 (1.24, 1.51) 0.001
antiarrhythmic 7,633 (4.0) 182 (384) 3.25 (2.79, 3.80) ,0.001 2.18 (1.87, 2.55) ,0.001
anticoagulants 21,977 (11.6) 454 (318) 3.07 (2.75, 3.42) ,0.001 2.05 (1.84, 2.29) ,0.001
lipid lowering 87,747 (46.2) 1,067 (175) 2.09 (1.88, 2.32) ,0.001 1.64 (1.47, 1.82) ,0.001
Notes: aadjusted for sex and age group. bJoint log likelihood test. cRenal disease as defined by microalbuminuria, proteinuria, or previous AKI admission.
Abbreviations: COPD, chronic obstructive pulmonary disease; AKI, acute kidney injury; py, person-years; CI, confidence interval; GOLD, Global initiative for chronic 
Obstructive lung Disease; CKD, chronic kidney disease; aCei, angiotensin-converting enzyme inhibitors; arB, angiotensin II receptor blocker.
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Table 2 Baseline characteristics of patients with COPD exacerbation (n=36,107) and odds ratios for coexistence of aKI (n=704)
Baseline patient 
characteristics
Total at 
baseline, n (%)
Concurrent 
AKI, n (%)
Crude odds ratio 
(95% CI)
P-valuea Adjustedb odds 
ratio (95% CI)
P-valueb
sex
Male 19,235 (53.3) 427 (2.2) 1 (reference) ,0.001 1 (reference) ,0.001
Female 16,872 (46.7) 277 (1.6) 0.74 (0.63, 0.86) 0.68 (0.58, 0.80)
age (years)
,50 1,547 (4.3) 6 (0.4) 1 (reference) ,0.001 1 (reference) 0.066
50–59 4,989 (13.8) 37 (0.7) 1.92 (0.81, 4.56) 1.55 (0.65, 3.71)
60–69 10,404 (28.8) 138 (1.3) 3.45 (1.52, 7.83) 1.93 (0.84, 4.45)
70–79 12,496 (34.6) 303 (2.4) 6.38 (2.84, 14.3) 2.28 (0.99, 5.25)
80–89 6,151 (17.0) 202 (3.3) 8.72 (3.86, 19.68) 2.37 (1.02, 5.50)
$90 520 (1.4) 18 (3.5) 9.21 (3.64, 23.33) 1.88 (0.72, 4.93)
region
london 3,811 (10.6) 88 (2.3) 1 (reference) 0.005 1 (reference) 0.035
Midlands 5,453 (15.1) 109 (2.0) 0.86 (0.64, 1.15) 0.84 (0.63, 1.13)
north england 12,054 (33.4) 193 (1.6) 0.69 (0.53, 0.89) 0.89 (0.70, 1.14)
south england 14,789 (41.0) 314 (2.1) 0.92 (0.72, 1.17) 0.71 (0.55, 0.92)
Comorbidities
Body mass index
Underweight 1,418 (3.9) 22 (1.6) 0.94 (0.60, 1.46) ,0.001 1.18 (0.75, 1.86) 0.002
normal 14,296 (39.6) 236 (1.7) 1 (reference) 1 (reference)
Overweight 12,056 (33.4) 221 (1.8) 1.11 (0.92, 1.34) 0.91 (0.76, 1.11)
Moderately obese 4,893 (13.6) 117 (2.4) 1.46 (1.17, 1.83) 1.23 (0.98, 1.55)
severely obese 1,345 (3.7) 38 (2.8) 1.73 (1.22, 2.45) 1.51 (1.05, 2.17)
Morbidly obese 643 (1.8) 20 (3.1) 1.91 (1.20, 3.04) 2.13 (1.31, 3.46)
Missing 1,456 (4.0) 50 (3.4) – –
COPD severity (gOlD stage)
I 3,669 (10.2) 50 (1.4) 1 (reference) 0.239 1 (reference) 0.292
II 13,690 (37.9) 253 (1.9) 1.36 (1.00, 1.85) 1.34 (0.98, 1.83)
III 9,473 (26.2) 165 (1.7) 1.28 (0.93, 1.76) 1.26 (0.91, 1.75)
IV 2,844 (7.9) 50 (1.8) 1.30 (0.87, 1.92) 1.37 (0.91, 2.07)
Missing 6,431 (17.8) 186 (2.9) – –
hypertension 19,517 (54.1) 480 (2.5) 1.84 (1.57, 2.16) ,0.001 1.35 (1.14, 1.59) ,0.001
Diabetes mellitus 8,044 (22.3) 193 (2.4) 1.32 (1.12, 1.57) 0.001 1.17 (0.98, 1.39) 0.083
angina 7,252 (20.1) 137 (1.9) 0.96 (0.80, 1.16) 0.676 0.74 (0.61, 0.89) 0.002
Myocardial infarction 5,382 (14.9) 118 (2.2) 1.15 (0.94, 1.41) 0.163 0.85 (0.69, 1.05) 0.125
Atrial fibrillation 7,028 (19.5) 186 (2.7) 1.50 (1.27, 1.78) ,0.001 1.08 (0.91, 1.29) 0.382
heart failure 7,645 (21.2) 258 (3.4) 2.19 (1.88, 2.56) ,0.001 1.27 (1.08, 1.50) 0.004
Coronary artery bypass graft 1,557 (4.3) 32 (2.1) 1.06 (0.74, 1.51) 0.758 0.82 (0.57, 1.19) 0.304
Pulmonary hypertension 942 (2.6) 23 (2.4) 1.27 (0.83, 1.93) 0.270 1.13 (0.73, 1.73) 0.591
CKD (egFr ml/kg/1.73 m2)
$90 6,320 (17.5) 35 (0.6) 1 (reference) ,0.001 1 (reference) ,0.001
60–89 16,885 (46.8) 145 (0.9) 1.56 (1.07, 2.25) 1.31 (0.89, 1.93)
30–59 11,481 (31.8) 341 (3.0) 5.50 (3.88, 7.79) 4.35 (2.96, 6.38)
15–29 1,258 (3.5) 128 (10.2) 20.30 (13.92, 29.72) 15.80 (10.40, 24.01)
,15 163 (0.5) 55 (33.7) 91.45 (57.47, 145.52) 73.74 (44.97, 120.93)
Medications
COPD medications 35,483 (98.3) 679 (1.9) 0.47 (0.31, 0.70) ,0.001 0.54 (0.36, 0.83) 0.005
antiplatelets 22,338 (61.9) 480 (2.2) 1.33 (1.13, 1.56) 0.001 0.94 (0.79, 1.11) 0.433
antidiabetes medications 5,683 (15.7) 153 (2.7) 1.50 (1.25, 1.80) ,0.001 1.32 (1.09, 1.59) 0.004
Beta blockers 11,746 (32.5) 274 (2.3) 1.33 (1.14, 1.55) ,0.001 1.09 (0.93, 1.27) 0.304
Diuretics 25,821 (71.5) 616 (2.4) 2.83 (2.26, 3.55) ,0.001 1.59 (1.25, 2.01) ,0.001
aCei/arB 19,347 (53.6) 468 (2.4) 1.74 (1.48, 2.03) ,0.001 1.23 (1.05, 1.45) 0.012
Vasodilators 1,730 (4.8) 14 (0.8) 0.40 (0.23, 0.68) 0.001 0.53 (0.31, 0.91) 0.021
alpha blockers 1,768 (4.9) 59 (3.3) 1.80 (1.38, 2.36) ,0.001 1.20 (0.90, 1.59) 0.218
Inotropes 5,417 (15.0) 161 (3.0) 1.70 (1.42, 2.03) ,0.001 1.19 (0.99, 1.43) 0.068
nitrates 7,115 (19.7) 129 (1.8) 0.78 (0.64, 0.96) 0.021 0.77 (0.62, 0.95) 0.016
Calcium channel blockers 13,405 (37.1) 312 (2.3) 1.29 (1.05, 1.57) 0.013 1.31 (1.07, 1.61) 0.010
antiarrhythmic 2,625 (7.3) 60 (2.3) 1.19 (0.91, 1.56) 0.197 0.85 (0.64, 1.11) 0.230
anticoagulants 6,976 (19.3) 168 (2.4) 1.32 (1.10, 1.57) 0.002 1.03 (0.86, 1.23) 0.768
lipid lowering 20,962 (58.1) 405 (1.9) 0.98 (0.84, 1.14) 0.775 1.01 (0.86, 1.17)** 0.941
Notes: aJoint log likelihood test. badjusted for sex, age group, and egFr. **evidence of collinearity with egFr, adjusted for age and sex only.
Abbreviations: COPD, chronic obstructive pulmonary disease; AKI, acute kidney injury; CI, confidence interval; GOLD, Global initiative for chronic Obstructive Lung 
Disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.
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Table 3 Univariable and multivariable Poisson regression analyses of the association of baseline characteristics with mortality following 
COPD exacerbation (n=36,107)
Baseline patient 
characteristics
Deaths, n (rate/1,000 
person-years)
Crude rate ratio 
(95% CI)
P-valuea Adjustedb rate 
ratio (95% CI)
P-valueb
sex
Male 8,102 (151) 1 (reference) ,0.001 1 (reference) ,0.001
Female 6,345 (131) 0.87 (0.84, 0.90) 0.87 (0.84, 0.90)
age (years)
,50 155 (35) 1 (reference) ,0.001 1 (reference) ,0.001
50–59 910 (58) 1.67 (1.41, 1.98) 1.73 (1.46, 2.05)
60–69 3,291 (103) 2.97 (2.53, 3.49) 3.21 (2.73, 3.77)
70–79 5,831 (166) 4.79 (4.08, 5.62) 5.24 (4.45, 6.17)
80–89 3,864 (274) 7.88 (6.71, 9.25) 8.37 (7.10, 9.88)
$90 396 (397) 11.44 (9.50, 13.78) 11.69 (9.66, 14.14)
region
london 1,413 (132) 1 (reference) ,0.001 1 (reference) ,0.001
Midlands 2,164 (146) 1.11 (1.04, 1.19) 1.13 (1.06, 1.21)
north england 5,899 (144) 1.09 (1.03, 1.16) 1.09 (1.03, 1.15)
south england 4,971 (139) 1.05 (0.99, 1.12) 1.13 (1.07, 1.20)
acute kidney injury 472 (512) 3.71 (3.39, 4.07) ,0.001 2.47 (2.24, 3.73) ,0.001
Body mass index
Underweight 751 (201) 1.37 (1.27, 1.48) ,0.001 1.41 (1.30, 1.52) ,0.001
normal 5,848 (147) 1 (reference) 1 (reference)
Overweight 4,425 (127) 0.86 (0.83, 0.90) 0.82 (0.79, 0.85)
Moderately obese 1,726 (118) 0.80 (0.76, 0.85) 0.83 (0.78, 0.87)
severely obese 478 (116) 0.79 (0.72, 0.87) 0.88 (0.80, 0.96)
Morbidly obese 229 (112) 0.76 (0.67, 0.87) 0.99 (0.87, 1.13)
Missing 990 (341) – –
COPD severity (gOlD stage)
I 886 (82) 1 (reference) ,0.001 1 (reference) ,0.001
II 4,095 (99) 1.21 (1.13, 1.30) 1.18 (1.10, 1.27)
III 3,983 (140) 1.72 (2.14, 2.52) 1.63 (1.52, 1.75)
IV 1,580 (189) 2.32 (2.14, 2.52) 2.30 (2.11, 2.50)
Missing 3,903 (295) – –
hypertension 7,654 (136) 0.93 (0.90, 0.96) ,0.001 0.82 (0.79, 0.84) ,0.001
Diabetes mellitus 3,058 (122) 0.83 (0.79, 0.86) ,0.001 0.84 (0.81, 0.87) ,0.001
angina 3,199 (146) 1.04 (1.00, 1.09) 0.030 0.93 (0.90, 0.97) ,0.001
Myocardial infarction 2,613 (168) 1.23 (1.18, 1.28) ,0.001 1.08 (1.03, 1.12) ,0.001
Atrial fibrillation 3,461 (171) 1.27 (1.22, 1.32) ,0.001 1.00 (0.96, 1.04) 0.844
heart failure 4,394 (212) 1.72 (1.66, 1.78) ,0.001 1.37 (1.32, 1.42) ,0.001
Coronary artery bypass graft 605 (127) 0.89 (0.82, 0.97) 0.007 0.85 (0.78, 0.92) ,0.001
Pulmonary hypertension 567 (207) 1.49 (1.37, 1.62) ,0.001 1.46 (1.34, 1.59) ,0.001
CKD (egFr in ml/kg/1.73 m2)
$90 1,741 (103) 1 (reference) ,0.001 1 (reference) ,0.001
$60 and ,90 5,981 (114) 1.14 (1.08, 1.20) 0.70 (0.66, 0.74)
$30 and ,60 5,763 (181) 1.76 (1.67, 1.86) 0.81 (0.76, 0.86)
$15 and ,30 842 (360) 3.50 (3.23, 3.80) 1.42 (1.30, 1.55)
,15 120 (476) 4.63 (3.85, 5.57) 1.84 (1.67, 2.44)
COPD medications 14,111 (139) 0.45 (0.40, 0.50) ,0.001 0.54 (0.49, 0.60) ,0.001
antiplatelets 9,421 (145) 1.08 (1.04, 1.11) ,0.001 0.87 (0.84, 0.90) ,0.001
antidiabetes medications 2,211 (125) 0.87 (0.83, 0.91) ,0.001 0.92 (0.88, 0.96) ,0.001
Beta blockers 4,351 (132) 0.91 (0.88, 0.94) ,0.001 0.89 (0.86, 0.92) ,0.001
Diuretics 11,744 (161) 1.73 (1.66, 1.80) ,0.001 1.29 (1.24, 1.35) ,0.001
aCei/arB 7,959 (141) 1.00 (0.97, 1.03) 0.876 0.87 (0.84, 0.90) ,0.001
Vasodilators 439 (83) 0.58 (0.52, 0.63) ,0.001 0.75 (0.68, 0.82) ,0.001
alpha blockers 773 (160) 1.14 (1.06, 1.22) 0.001 0.99 (0.92, 1.06) 0.730
Inotropes 3,036 (203) 1.55 (1.49, 1.61) ,0.001 1.22 (1.17, 1.27) ,0.001
nitrates 3,095 (148) 1.06 (1.12, 1.11) 0.002 1.00 (0.96, 1.04) 0.961
(Continued)
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drugs were all associated with lower mortality before and 
after adjusting for age, sex, and eGFR. Angina and anti-
platelet medications were associated with lower mortality 
after adjustment for age and sex (Table 3).
AKI at the time of COPD exacerbation was associated 
with a substantially higher mortality rate (logrank: P,0.001), 
particularly during the first 6 months (Figure 2). In all, 50% 
of patients without AKI survived approximately 5.5 years, 
while 54% of patients suffering from AKI survived 6 months. 
Mortality among patients with AKI at the first COPD exacer-
bation was 512/103 py. The presence of AKI at the first COPD 
exacerbation during follow-up was associated with a 2.47-fold 
higher mortality rate after adjusting for age, sex, and eGFR 
(95% CI: 2.24, 3.73) than those without AKI (Table 3). In the 
first 6 months after a hospitalization for COPD exacerbation, 
the risk of death was 1.80 (95% CI: 1.61, 2.03) times higher in 
patients with concomitant AKI than those without after adjust-
ing for age, sex, and baseline renal function, which reduced 
to 1.37 (95% CI: 1.16, 1.62) thereafter (Table 4).
Discussion
AKI is common among COPD patients who exacerbate. 
These people have a high mortality, particularly in the first 
6 months after the event. This mortality is partially explained 
by having other comorbidities (eg, DM, HF, preexisting 
renal disease). However, the underlying comorbidities do 
not fully explain AKI mortality associations seen. This sug-
gests that there are potentially modifiable factors that could 
prevent mortality associated with AKI in patients with COPD 
exacerbations.
The incidence rate of AKI admission in a COPD cohort 
was calculated to be 128/105 py. The true incidence of AKI 
in the general population is not known, due to scarcity of 
studies.27 The strongest predictor of AKI is baseline renal 
function. This is supported by previous literature that 
0.00
0.25
0.50
0.75
1.00
704 185 58 12 1 0AKI = AKI
35,403 19,916 9,911 4,180 983 0AKI = no AKI
Number at risk
0 2 4 6 8 10
Follow-up time (years)
No AKI
Log rank
test: P<0.001
AKI
Kaplan–Meier survival estimates
Figure 2 Kaplan–Meier survival curve stratified by AKI among patients with a 
COPD exacerbation (n=36,107).
Abbreviations: aKI, acute kidney injury; COPD, chronic obstructive pulmonary 
disease.
Table 4 Multivariable model of mortality following COPD 
exacerbation (n=36,107)
Variable Adjusted RR (95% CI) P-value
,6 months follow-up
aKI 1.80 (1.61, 2.03) ,0.001
$6 months follow-up
aKI 1.37 (1.16, 1.62) ,0.001
age at entry in years (ref ,50)
$50, ,60 1.67 (1.41, 1.98) ,0.001
$60, ,70 2.83 (2.41, 3.34)
$70, ,80 4.06 (3.45, 4.78)
$80, ,90 5.41 (4.58, 6.38)
$90 6.90 (5.70, 8.35)
sex: female 0.89 (0.86, 0.92) ,0.001
egFr in ml/kg/1.73 m2 (ref $90)
$60 and ,90 0.78 (0.74, 0.83) ,0.001
$30 and ,60 0.88 (0.82, 0.93)
$15 and ,30 1.04 (0.95, 1.13)
,15 1.02 (0.84, 1.24)
Abbreviations: COPD, chronic obstructive pulmonary disease; rr, risk ratio; 
CI, confidence interval; AKI, acute kidney injury; Ref, reference; eGFR, estimated 
glomerular filtration rate.
Table 3 (Continued)
Baseline patient 
characteristics
Deaths, n (rate/1,000 
person-years)
Crude rate ratio 
(95% CI)
P-valuea Adjustedb rate 
ratio (95% CI)
P-valueb
Calcium channel blockers 5,091 (130) 0.87 (0.85, 0.91) ,0.001 0.83 (0.80, 0.86) ,0.001
antiarrhythmic 1,301 (139) 0.66 (0.64, 0.68) ,0.001 0.68 (0.65, 0.70) ,0.001
anticoagulants 3,156 (153) 1.06 (1.02, 1.11) 0.002 1.13 (1.08, 1.18) ,0.001
lipid lowering 7,534 (118) 0.87 (0.84, 0.91) ,0.001 0.91 (0.87, 0.95) ,0.001
Time from exacerbation
,6 months 1 (reference) ,0.001 1 (reference) ,0.001
$6 months 0.020 (0.19, 0.0.21) 0.024 (0.023, 0.025)
Notes: aJoint log likelihood test. badjusted for sex, age group, and egFr.
Abbreviations: COPD, chronic obstructive pulmonary disease; CI, confidence interval; GOLD, Global initiative for chronic Obstructive Lung Disease; CKD, chronic kidney 
disease; eGFR, estimated glomerular filtration rate; ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker.
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suggests that CKD is a risk factor for AKI.11,12 Our study 
observed a similar trend in COPD patients. Patients likely to 
suffer from renal impairment (including microalbuminuria 
and proteinuria) had a larger observed incidence of AKI 
than those with known CKD, possibly due to the absence of 
education or treatment in this group. Being female is shown 
to be protective; AKI was 35% lower in females within this 
study sample. The risk of AKI increased with age and BMI. 
Other strong predictors (adjusted RR $2.5) included DM, 
HF, and the use of diuretics and diabetic medications.
COPD severity does not have a rising effect on AKI. 
The incidence rate rises gradually but then drops at GOLD 
stage IV. This could be a result of the higher mortality rate 
in the most severe COPD group, meaning that they are 
more likely to die before achieving the outcome of interest 
(AKI hospitalization).28 The prevalence of concurrent AKI 
in COPD exacerbations is observed to be 1.9%. There are 
no previous studies investigating the prevalence of AKI in 
COPD exacerbations. The predictors of concomitant AKI in 
COPD exacerbations are less abundant than those for AKI 
overall among the stable COPD cohort. Again, being female 
is observed to reduce the chance of the patient also having 
AKI by approximately one-third. Notably, age is negligible 
once eGFR and sex are taken into account.
The mortality rate of patients suffering from the first 
COPD exacerbation in the presence of concomitant AKI is 
512/103 py (51.2%) compared to 138/103 py (13.8%) in those 
without AKI, producing a mortality RR of 3.71 (95% CI: 
3.39, 4.07). According to the UK Renal Association, AKI 
is commonly seen in hospitalized patients with a mortality 
rate ranging from 10% to 80%, which is consistent with this 
study’s results.29 Uncomplicated AKI has a mortality rate of 
up to 10%, while that with multiorgan failure holds a mortality 
rate of more than 50%.29 The estimated mortality rate of .10% 
in this study shows consistency with previous studies, but 
comparison cannot be achieved with mortality associated with 
multiorgan failure as the extent of organ failure of the patients 
in this study is not known. A multicenter prospective study in 
the UK measured the COPD exacerbation mortality rate to be 
23%.30 Again, a .23% mortality in COPD exacerbation in the 
presence of AKI is consistent with previous literature.
The mortality rate, adjusting for age and eGFR, was 
estimated to be 13% lower in females compared to males. As 
expected, mortality increases with older age groups despite 
sex and baseline renal function. Higher than normal BMIs are 
protective in the context of COPD exacerbations adjusting for 
age, sex, and renal function, while the opposite is observed for 
lower BMIs. This trend is consistent with the BODE index, 
which suggests that patients with BMI $21 kg/m2 are at a 
significantly lower risk of death than those ,21 kg/m2.31 Mor-
tality expectedly increases with worsening COPD (according 
to GOLD staging), which is compatible with Mannino et al’s 
findings.28 Other than baseline renal function and degree of 
COPD, we did not find any other strong predictors.
Similar to previous studies, we demonstrated higher 
mortality rates closer to the time of COPD exacerbation.32,33 
There is a notable steep increase in deaths within the first 
6 months post COPD exacerbation, contributing to a .50% 
mortality in the first year after COPD exacerbation in patients 
with concomitant AKI.
Limitations
AKI is a known adverse effect of nonsteroidal anti-inflammatory 
drugs. Nonsteroidal anti-inflammatory drugs are available over 
the counter without a prescription, making recording these data 
almost impossible. This study relies on GP documentation of 
death (from CPRD), and the date of death recorded may not be 
accurate. Of the total 189,561 COPD patients, 125,364 (66%) 
were lost to follow-up over the 9 years.
We calculated eGFR without adjusting for ethnicity. 
Patients of Black ethnicity produce higher eGFR on estima-
tion, and therefore, some patients’ baseline renal functions are 
underestimated causing differential misclassification of eGFR. 
However, according to the 2011 Census, the Black population 
only comprises 3% of the UK population; hence, this issue is 
likely to have a negligible effect on the associations seen.34
Information provided on CKD status is potentially 
biased as patients at high risk of kidney disease (such as 
diabetics and hypertensive patients) are monitored closer 
for signs of CKD than those with no risk factors. Addi-
tionally, assuming that those without CKD codes have 
no kidney disease is probably conservative, as we are 
likely to have missed more cases. Findings are indicative 
of underrecognition of kidney problems in people with 
COPD as evidenced by finding a subgroup of people with 
severe kidney function impairments without corresponding 
primary care CKD Read Code.
Patients required a COPD diagnosis for inclusion: some 
patients with stable COPD and less severe breathing difficulty 
may not seek any medical attention. This raises the issue of 
selection bias, as the COPD patients selected for the study 
are not a true representative of the population distribution 
of COPD severity. Furthermore, on identifying patients 
hospitalized with COPD exacerbation, ICD-10 codes are 
used. These codes may be presented inaccurately. There is a 
certain ICD-10 code for patients admitted into hospital with 
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COPD exacerbation; separate codes for lower respiratory tract 
infection and pneumonia are also available to choose from. 
COPD patients coded for a chest infection may have also had 
an exacerbation, and therefore, the prevalence of COPD exac-
erbation among COPD patients is underestimated. Moreover, 
the COPD exacerbation sample is not representative of the true 
COPD exacerbations. The same can be said about the AKI 
codes. Since 2008, the rates of AKI coding have been steadily 
increasing (note that this cohort study started in 2004), hence 
again, underestimation of clinical condition.35
Potential confounding factors are assessed during this 
study; however, unavailable and unknown potential con-
founders are not considered. Most notably, smoking status 
and socioeconomic status could confound the association 
between AKI and mortality.
This study had prespecified investigation of mortality in 
COPD exacerbations and concomitant AKI versus COPD 
exacerbation alone. Since we are already aware that having 
AKI increases mortality, it would also be interesting to see 
if patients with concurrent AKI and COPD exacerbations 
have a higher mortality rate than AKI alone.36 Additionally, 
we did not have information on different causes of AKI in 
this population. It would be interesting to assess whether 
COPD patients have more prerenal AKI related to comor-
bidities or more postrenal AKI due to anticholinergic use 
for example.
In conclusion, AKI is considered a predictor of poor 
outcome in patients with COPD exacerbation. Consequently, 
it is recommended for patients suffering from simultaneous 
AKI and COPD exacerbation to be identified as higher risk 
patients and hence monitored more closely, especially early 
after hospital discharge.
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